Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02443116
Registration number
NCT02443116
Ethics application status
Date submitted
11/05/2015
Date registered
13/05/2015
Date last updated
11/09/2020
Titles & IDs
Public title
Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
Query!
Scientific title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Multiple-center Study With Additional Open-label Single-blind and Placebo-controlled 24-Week Histology Cohorts to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for Up to 24 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
Query!
Secondary ID [1]
0
0
15-0105
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Nonalcoholic Steatohepatitis (NASH)
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Diet and Nutrition
0
0
0
0
Query!
Obesity
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - NGM282
Other interventions - Placebo
Placebo Comparator: Cohort 1 - Placebo - Cohort 1 - Placebo
Experimental: Cohort 1 - NGM282 3mg - Cohort 1 - NGM282 3mg
Experimental: Cohort 1 - NGM282 6mg - Cohort 1 - NGM282 6mg
Experimental: Cohort 2 - NGM282 0.3mg - Cohort 2 - NGM282 0.3mg
Placebo Comparator: Cohort 2 - NGM282 1mg - Cohort 2 - NGM282 1mg
Experimental: Cohort 2 - NGM282 3mg - Cohort 2 - NGM282 3mg
Experimental: Cohort 3 - NGM282 1mg - Cohort 3 - NGM282 1mg
Placebo Comparator: Cohort 4 - Placebo - Cohort 4 - Placebo
Experimental: Cohort 4 - NGM282 1mg - Cohort 4 - NGM282 1mg
Other interventions: NGM282
Other interventions: Placebo
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in absolute liver fat content as measured by MRI from Baseline to Week 24
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
24 weeks
Query!
Secondary outcome [1]
0
0
Change in percentage liver fat content as measure by MRI from Baseline to Week 24
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
24 weeks
Query!
Eligibility
Key inclusion criteria
- Males or females, between 18 and 75 years of age, inclusive
- Histologically confirmed NASH diagnosis
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Clinically significant acute or chronic liver disease
- Prior liver transplantation
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/07/2015
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
17/01/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
254
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
NGM Clinical Study Site 703 - Sydney
Query!
Recruitment hospital [2]
0
0
NGM Clinical Study Site 704 - Adelaide
Query!
Recruitment hospital [3]
0
0
NGM Clinical Study Site 701 - Melbourne
Query!
Recruitment hospital [4]
0
0
NGM Clinical Study Site 705 - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Sydney
Query!
Recruitment postcode(s) [2]
0
0
- Adelaide
Query!
Recruitment postcode(s) [3]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Tennessee
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Virginia
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Washington
Query!
Country [12]
0
0
Puerto Rico
Query!
State/province [12]
0
0
San Juan
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
NGM Biopharmaceuticals, Inc
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
NGM Biopharmaceuticals Australia Pty Ltd
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in
patients with nonalcoholic steatohepatitis.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02443116
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
NGM Study Director
Query!
Address
0
0
NGM Biopharmaceuticals, Inc
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02443116
Download to PDF